NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment

Shohei Yoshimoto1,2 · Hiromitsu Morita3 · Miho Matsuda4 · Yoshinori Katakura5 · Masato Hirata2 · Shuichi Hashimoto1

Received: 8 July 2020 / Revised: 26 August 2020 / Accepted: 27 August 2020 / Published online: 8 September 2020 © The Author(s) 2020. This article is published with open access

Abstract
Epidermal growth factor receptor (EGFR) is highly expressed in several types of cancer cells including oral squamous cell carcinoma (OSCC). EGF/EGFR signaling is recognized as an important molecular target in cancer therapy. However, cancer cells often become tolerant to EGF/EGFR signaling-targeted therapies. In the tumor microenvironment, the tumor incites inflammation and the inflammation-derived cytokines make a considerable impact on cancer development. In addition, hyperosmolarity is also induced, but the role of osmotic stress in cancer development has not been fully understood. This study demonstrates molecular insights into hyperosmolarity effect on OSCC development and shows that NFAT5 transcription factor plays an important functional role in enhancing the oral cancer cell proliferation by inducing the EGFR translocation from the endoplasmic reticulum to the plasma membrane through increase the expression of DPAGT1, an essential enzyme for catalyzing the first committed step of N-linked protein glycosylation. These results suggest that hyperosmolarity-induced intra-nuclear translocation of NFAT5 essential for DPAGT1 activation and EGFR subcellular translocation responsible for OSCC tumor progression.

Introduction
Epidermal growth factor receptor (EGFR) is highly expressed in several carcinomas including oral squamous cell carcinomas (OSCC). EGF binds to the extracellular domain of EGFR and induces its dimerization, then intrinsic kinase activity is activated. Subsequently the intracytoplasmic domain of EGFR is autophosphorylated at multiple tyrosine residues. These phosphorylated tyrosine residues are bound to several adapter proteins, the EGF/EGFR signaling pathway is activated, which plays a critical role in cancer cells proliferation [1]. Thus, the EGF/EGFR signaling pathway is recognized as an important molecular target in cancer therapy. Some informative studies report the efficacy of EGFR-targeted therapies on cancer progression using EGFR tyrosine kinase inhibitors (TKIs) or EGFR-neutralizing antibodies [2, 3]. However, drug resistance sometimes occurs in these molecularly targeted therapies [4]. In addition, mutations of some genes such as TP53, CDKN2A, PTEN, PIK3CA, and HRAS were reported in OSCC [5, 6]. Therefore, it is essential to develop a new therapeutic strategy in addition to clarifying the mechanisms of anti-tumor drug resistance in molecularly targeted cancer therapies.

The cancer microenvironment is constantly inflamed and consist of cancer cells, connective tissues, vascular tissues and inflammatory cells [7]. It is a reasonable framework that inflammatory responses against cancer cells play an important role in cancer development [7, 8].
Several studies have shown that tumor associated macrophages play a pivotal role in cancer-related inflammation and progression of disease [9, 10]. Although in the cancer microenvironment, osmolarity is elevated under cancer cell-related inflammatory conditions, the relationship between hyperosmolarity and cancer cells proliferation remains unclear.

Under hyperosmotic conditions, nuclear factor of activated T cells 5 (NFAT5), a transcription factor, is involved in the regulation of cell homeostasis. NFAT5 is a transcription factor of the Rel family which also comprises the NF-κB and NFAT1-4 proteins [11]. NFAT1-4’s functional abilities are upregulated in a calcium/calcineurin-independent manner by binding to calcineurin through their N-terminal calcineurin-binding domain site. In contrast, NFAT5 lacks the calcineurin-binding domain and is upregulated in a calcium/calcineurin-independent manner. NFAT5 is also known as tonicity-response element-upregulated in a calcium/calcineurin-independent manner. NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment 39

**Materials and methods**

**Cell cultures under normal and hyperosmotic conditions**

The human tongue squamous cell carcinoma cell line HSC-3 was kindly donated by Dr. H. Takeuchi (Kyushu Dental University, Kitakyushu, Japan). HSC-3 was purchased from JCRB cell bank (Osaka, Japan). Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Fisher Scientific, Waltham, MA), supplemented with 10% fetal bovine serum (FBS, PAA Laboratories, Pasching, Austria) at 37 °C in 5% CO₂. In total, 25 mM glucose or 5.5 mM glucose contained DMEM was used as a high glucose (HG) or low glucose (LG) culture medium, respectively. To increase the osmolarity of medium, mannitol (Wako, Osaka, Japan) was added. The osmolarity of each solution was measured by osmometer (OM-801; Vogel GmbH & Co. KG, Fernwald, Germany). Cells were reseeded for the next passage after the tryptic (Thermo Fisher Scientific) dispersion when culture cells reached ~80% confluency.

**Western blot analyses**

Cells were homogenized in an ice-cold lysis buffer and centrifuged for 30 min at 4 °C. The supernatants (20 μg) were separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidifluoride membranes (Millipore, Darmstadt, Germany). Immunoblot analyses were performed using the following primary antibodies; rabbit anti-EGFR and rabbit anti-phospho-EGFR (1:1000, Cell Signaling Technology, Danvers, MA), rabbit anti-NFAT5 (1:1000, Abcam, Cambridge, MA) and rabbit anti-DPAGT1 (1:1000, Sigma-Aldrich, St.Louis, MO) antibodies. A rabbit anti-human β-actin antibody (1:2000, Cell Signaling Technology) was used as an internal control. Blots were developed with horseradish peroxidase-linked secondary antibodies (1:3000, GE Healthcare, Cleveland, OH) and visualized by the enhanced chemiluminescence system using ImmunoStar Zeta (Wako), and the image density of bands were detected by LAS-4000 (GE Healthcare, Little Chalfont, UK). For the biotinylation assay, culture cells reached 80% confluency in a 10 cm diameter dish were lysed in the lysis buffer, and followed by an incubation in the cold biotin reagent (1 mg/ml sulfo-NHS-SS-biotin; Thermo Fisher Scientific) for 30 min at 4 °C. After the biotin-treated lysate was centrifuged at 18,000 × g for 10 min at 4 °C, the supernatant was incubated with 300 μL of cold avidin beads (Thermo Fisher Scientific) at 4 °C for 2 h and centrifuged at 3500 × g for 30 min at 4 °C. The supernatants were aspirated, and the beads were washed three times with 1 ml of the cold lysis buffer and once with a cold 500 mM NaCl and Tris-HCl (pH 7.5) buffer, and then once with a cold 10 mM Tris-HCl (pH 7.5) buffer. The beads were boiled with 50 μl of Laemmli sample buffer, and a 20-μl aliquot was analyzed by SDS-PAGE. For the deglycosylation, cell lysates were boiled in a 100 mM sodium phosphate buffer for 10 min in the presence of 2.5% 2-mercaptoethanol and 2% SDS. N-linked carbohydrates were removed by a treatment with 2 unites of N-glycosidase F (Roche, Basel, Switzerland) per 20 μg proteins. The mixture was incubated for 18 h at 37 °C. After the incubation, Western blotting analysis was carried out.

**Fluorescent immunocytochemistry**

Cells were washed in a 1× phosphate buffered saline (PBS) (−) and fixed with a 4% paraformaldehyde (PFA) for 10 min at room temperature. After washing in a PBS (−), cells were permeabilized with digitonin (100 μg/ml, Wako) and blocked with 2.5% bovine serum albumin (BSA, Sigma-Aldrich). After lightly washing in a PBS (−), cells were incubated with the following each primary antibody; rabbit anti-EGFR antibody (1:100, Cell Signaling Technology),
rabbit anti-NFAT5 antibody (1:100, Abcam), rabbit anti-DPAGT1 antibody (1:100, Sigma-Aldrich), mouse anti-KDEL antibody (1:100, MBL, Nagoya, Japan), for overnight at 4°C. After three times washing in a PBS (−), cells were then incubated with the following each secondary antibody; Alexa Fluor 488 or 594-conjugated goat anti-rabbit or -mouse IgG (1:1000 dilution), for 1 h at room temperature. Nuclear counter staining was done with DAPI (1:3000 dilution) for 1 h at room temperature. After washing, the cells were mounted with PermaFluor mountant for visualization. Samples were visualized with a confocal microscope (LSM700, Carl Zeiss, Oberkochen, Germany). The images were processed in ZEN 2010B Sp1 Ver. 6.0.0.485 software (Carl Zeiss).

**Cell proliferation assays**

The evaluation of the cell proliferation activity was done using the Cell Counting Kit-8 (WST-8, Dojindo, Kumamoto, Japan) and BrdU Proliferation Colorimetric ELISA using the Cell Counting Kit-8 (WST-8, Dojindo, Kumamoto, Japan) and BrdU Proliferation Colorimetric ELISA Kit (Exalpna Biologicals, Shirley, MA) according to the manufacturer’s protocols. Briefly, cells were plated in 96-well plates at a ratio of 1 x 10⁵ cells/well and cultured in the LG or hyperosmotic conditioned medium with or without inhibitors, CP380736, a specific EGFR inhibitor, and genistein, a nonspecific TKI (Sigma-Aldrich), for 72 h at 37°C in 5% CO₂. The culture cells in each treatment were incubated with 10μl of tetrazolium substrate for 1 hr or 20 μl of BrdU for 6 h, then the absorbance was measured at a wavelength of 450 nm.

**NFAT5 gene knockdown assays by short hairpin RNA (shRNA)**

The oligonucleotides that contain the siRNA-expressing sequences targeting NFAT5 (sh-NFAT5#1 top 5’-GATCC CCCAACATGCGCTTGGAAATCTCAATTCGGAAGAGTTGAA TTCCAGGCATGTTGTGGTTTAT-3’, bottom 5’-AGCTTAA AAAAAACATGCGCTTGGAAATCTCAATTCGGAAGAGTTGAA TTCCAGGCATGTTGTGGTTG-3’; sh-NFAT5#2 top 5’-GAT CCCCCCCAGTCTTCAATGTAAATCCAGAGTGTACATTTGTTTTTAT-3’, bottom 5’-AGCTTAAAACACGTTCTTCAAATGTAAATCCAGAGTTGA TTCCAGGCATGTTGTGGTTG-3’; sh-NFAT5#3 top 5’-GAT CCAGGCATGTTGTGGTTG-3’; sh-NFAT5#4 top 5’-GAT CCAGGCATGTTGTGGTTG-3’; sh-NFAT5#5 top 5’-GAT CCAGGCATGTTGTGGTTG-3’; sh-NFAT5#6 top 5’-GAT CCAGGCATGTTGTGGTTG-3’; sh-NFAT5#7 top 5’-GAT CCAGGCATGTTGTGGTTG-3’) were annealed, and cloned into the pSUPER.retro.puro vector (OligoEngine, Seattle, WA). Viral supernatants were produced after transfection of 293 T cells with pGag-pol, pVSV-G and individual expression vector using the HilyMax (Dojindo). The cells were cultured at 37 °C in DMEM supplemented with 10% FBS for 24 h. The target cells were infected with each collected viral supernatant in the presence of 10 μg/ml polybrene (Merck-Millipore, Billerica, MA). After infection, the cells were cultured in the selection medium with 2 μg/ml puromycin (Enzo Life Science, Farmingdale, NY) for 48 h at 37 °C to get the cells showing NFAT5 gene integration in their own genomic DNA.

**Real-Time-quantitative PCR (RT-qPCR) analyses**

Total RNA was purified using RNeasy Mini Kit (Qiagen, Hilden, Germany), and cDNA was prepared using the ReverTra Ace (Toyobo, Osaka, Japan), according to the manufacturer’s protocols. RT-qPCR was performed using KOD SYBER qPCR Mix (Toyobo) and Thermal Cycler Dice Real Time System TP-960 (Takara, Shiga, Japan). When samples were analyzed, NFAT5 or DPAGT1 mRNA expression levels were normalized by the corresponding GAPDH mRNA expression level. The PCR primer sequences used were as follows: NFAT5 forward 5’-AGGA TGAGGGGTGTGGATTG-3’, reverse 5’-GCTTCTGCTTT GGATTTCCGT-3’; DPAGT1 forward 5’-GGGCGTTTCTT GCCCTCTAC-3’, reverse 5’-CTGGCCCAAGTTCTTATCC CC-3’; GAPDH forward 5’-ATACCCATCTTCCAGGAG CGAG-3’, reverse 5’-TGGCATGAGACTGTGGTCATG-3’.

**In situ Proximity Ligation Assay**

In situ Proximity Ligation Assay (in situ PLA) was performed to investigate co-localization of proteins using Duolink™ (Sigma-Aldrich), according to the manufacturer’s protocol. In brief, cells were fixed with 4% PFA and incubated with a pair of primary antibodies directed to EGFR (Cell Signaling Technology) and to KDEL (MBL) in 2.5% BSA. This was followed by washing with a wash buffer and consecutive 1 h incubation with corresponding PLA probes, to which oligonucleotides secondary antibodies were conjugated (mouse minus and rabbit plus). The cells were washed and incubated with the ligation solution for 30 min. After washing with a wash buffer, the cells were treated with the polymerase for amplification for 100 min, and then mounted with the Mounting Media for visualization. Samples were viewed with a microscope (BZ-9000, KEYENCE, Osaka, Japan). Quantitative fluorescence cell image analysis was performed using the BZ-II Analyzer. exe ver. 2.1 (KEYENCE).

**Chromatin immunoprecipitation**

Chromatin immunoprecipitation (ChIP) was performed on lysates from HSC-3 cells using the SimpleChIP Kits (Cell Signaling Technology) and ChIP grade anti-NFAT5 antibody (Abcam). Binding of NFAT5 to DPAGT1 promoter region was detected by PCR. The PCR primer sequences used were as follows: forward primer, 5’-GGGCGTTTCTT GCCCTCTAC-3’, and reverse primer, 5’-TGGCATGAGACTGTGGTCATG-3’.
**Tumorigenicity analyses**

HSC-3 cells (1 × 10⁶ cells) in 0.2 ml of PBS were injected subcutaneously into the right flank of the 8-week-old female BALB/cAJcl-nu mice (CLEA Japan, Inc, Tokyo, Japan) and maintained at the Center for Animal Resources of Fukuoka Dental College under specific pathogen-free (SPF) conditions. The mice were handled in accordance with the animal care policy of Fukuoka Dental College. After 1 week from the injection, a microosmotic pump (ALZET, model 1004; DURECT, Cupertino, CA) was implanted in the right flank to sustain the release of PBS or mannitol (289.5 μg/mouse/day) into the microenvironment of the transplanted HSC-3 cells. Each tumor size was measured with calipers every 3 or 4 days. Upon completion of the tumor study, mice were euthanized by isoflurane. Tumor volume was calculated as \(ab^2/2\) (mm³), where \(a\) and \(b\) are the largest and smallest central cross-sectional dimensions, respectively. At 26 days after the HSC-3 cell transplantation, tumors were extracted after the euthanasia treatment.

**Clinicopathological information**

This clinical study using the patient’s information was done under the permission of the ethics committee in Fukuoka Dental College (# 312). The 36 cases (male/female: 24/12, mean age: 60.3 years (range: 27–88 years)) examined in this study consisted of 8 oral epithelial dysplasia (OED) (Histological grade; moderate: 5, severe and carcinoma in situ: 3) and 28 OSCC (Histological differentiation; well: 11, moderate: 10, moderate to poor and poor: 7). These Japanese patients underwent surgery at Fukuoka Dental College Hospital between 2009 and 2018. The patients were not prescribed chemotherapy or irradiation before surgery. The histological classification was performed according to the criteria of the “WHO Classification of Head and Neck Tumours” [15].

**Immunohistochemical procedure**

Immunohistochemistry was performed as previously described [16]. Briefly, all surgical specimens were fixed in formalin and embedded in paraffin, then cut into 4 μm-thick sections for H.E. and immunohistochemical staining. For the antigen retrieval, the sections were autoclaved for 5 min at 121 °C in 0.01 M citrate buffer solution, pH 6.0. The sections were incubated with the primary antibodies (mouse anti-human NFAT5 antibody, 1:200; rabbit anti-human EGFR antibody, 1:200; rabbit anti-human DPAGT1 antibody, 1:200) at 4 °C for overnight. These sections were then incubated with biotin-labeled antibody (Agilent, Santa Clara, CA), followed by the streptavidin-biotin-peroxidase complex method. For the immunofluorescent histochemical staining, after the incubation with each primary antibody, the sections were treated with immunofluorescent labeled secondary antibodies at room temperature for 1 h. Sections were mounted using VECTASHIELD (Vector Lab., Burlingame, CA) and visualized at the appropriate wavelength using a fluorescence microscope (Axio Vert. A1, Carl Zeiss).

**Immunohistochemical assessment**

We randomly chose three areas in each dysplastic or cancerous lesion in one case and counted the number of cells positive for nuclear NFAT5 or cytoplasm DPAGT1 in at least 300 dysplastic or cancer cells included in one chosen area. The degree of positivity of immunoreaction in each area was determined according to the modified method of the one originally described by Allred et al [17]. Briefly, the percentage of immunostaining-positive dysplastic or cancer cells was described as proportion score (PS) [scored on a scale of 0–3; 0: 0%, 1: <10% (NFAT5 and DPAGT1), 2: <30% (NFAT5) or 50% (DPAGT1), 3: equal or more than 30% (NFAT5) or 50% (DPAGT1)]. Staining intensity was also described as intensity score (IS) [scored on a scale of 0–3; 0: negative, 1: weak positive, 2: intermediate positive, 3: strong positive]. The proportion and IS were then summed to produce total score (TS) (TS = PS + IS) [scored on a scale of 0, 2–6].

**Statistical analyses**

All data were expressed as the mean ± standard error of the mean (SEM). Student’s t test, Dunnett’s test, one-way analysis of variance and Mann–Whitney U test were used for statistical evaluations. Statistical significance was set as \(p < 0.05\), \(*p < 0.01\) and \(**p < 0.001\).

**Results**

**EGFR is translocated from the cytoplasm to the plasma membrane in OSCC cells under hyperosmotic conditions**

We first examined the subcellular localization of EGFR in HSC-3 cells cultured in either a HG or a LG medium. Immunofluorescent cytochemical staining revealed that EGFR was largely located in the plasma membrane when cells were cultured in a HG medium (Fig. 1a(a)). Conversely, EGFR was largely located in the cytoplasm when cells were cultured in a LG medium (Fig. 1a(b)). On the
other hand, when cells were maintained under hyperosmotic conditions by the addition of mannitol, translocation of EGFR from the cytoplasm toward the plasma membrane was observed (Fig. 1a(c)). The same tendencies were observed in HSC-4 cells (Supplementary Fig. 1).

We next examined the expression of EGFR protein by Western blotting. When cells were maintained in a HG medium, EGFR was only detected as a band with an apparent molecular mass of 170 kDa. However, in a LG medium, we detected not only a 170 kDa band but also a 140 kDa band. Moreover, when cells were cultured in a LG medium under hyperosmotic conditions, a decrease in the 140 kDa band was observed (Fig. 1b). To examine which EGFR form came from which subcellular compartment, the cytoplasm or the plasma membrane, we extracted cell surface proteins and separated them by SDS-PAGE. Only the 170 kDa band was detected in the plasma membrane fraction of cells cultured in both the LG and HG medium (Fig. 1c). However, the 140 kDa band was detected in the proteins from whole cell lysates of cells cultured only in a LG medium.

To confirm if the differences between the two forms of EGFR was related to glycosylation, we employed N-glycosidase F, which cleaves carbohydrate chains of glycoproteins. With this treatment, only a 140 kDa band could be detected in both the LG and HG medium (Fig. 1d). These results indicate that the 170 kDa form of EGFR was a glycosylated form of 140 kDa EGFR found in the plasma membrane, while the 140 kDa form of EGFR was a nonglycosylation form found in the cytosol.
NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment

EGFR signaling plays a key role in the acceleration of HSC-3 cell proliferation by hyperosmotic stimuli

To examine the effect of hyperosmolarity on the HSC-3 cell proliferation, we performed WST (water-soluble tetrazolium) and BrdU assays. The WST and the BrdU assay ratios were both upregulated by hyperosmotic stimuli (Fig. 1e, f). However, upregulation was inhibited by the treatment of CP380736, a specific EGFR inhibitor, or genistein, a nonspecific TKI (Fig. 1e, f) with both assays. These results indicate that EGFR signaling plays a key role in the acceleration of OSCC cell proliferation by hyperosmotic stimuli.

NFAT is essential for the glycosylation of EGFR

NFAT5 has been reported to play a pivotal role in gene expression in response to extracellular hyperosmotic conditions. In our analyses, NFAT5 expression was observed in the cytoplasm of HSC-3 cells. However, NFAT5 expression was found in the nucleus of HSC-3 cells in the hyperosmotic culture condition (Fig. 2a; green in a and c). The same tendencies were observed in HSC-4 cells (Supplementary Fig. 2A).

To determine the effect of the change of the NFAT5 subcellular localization under hyperosmotic conditions on EGFR expression, we depleted NFAT5 from HSC-3 cells using short hairpin RNA against NFAT5 (shNFAT5). We first confirmed that shNFAT5 significantly repressed the NFAT5 expression (Fig. 2b). In HSC-3 cells cultured with no shNFAT5 treatment, the expression of phosphorylated EGFR (pEGFR) was observed under normal osmotic conditions and was increased with the hyperosmotic stimuli (Fig. 2c, pEGFR in Control sh(-)). On the other hand, no pEGFR expression was observed in NFAT5 silenced cells under the normal osmotic and hyperosmotic stimuli conditions (Fig. 2c, pEGFR in shNFAT5). In addition, in accordance with the increase of hyperosmotic stimuli, the expression of 140 kDa EGFR under normal osmotic conditions was decreased with sh(-) culture condition but was not decreased with the treatment of shNFAT5 culture condition. (Fig. 2c, EGFR in Control sh(-)). In contrast, in NFAT5 silenced cells, the expression of 140 kDa EGFR was observed but no significant changes were observed with hyperosmotic stimuli (Fig. 2c, EGFR in shNFAT5). To confirm the difference between the 140 and 170 kDa EGFR, we focused on the glycosylation status of EGFR. Protein glycosylation is initiated in the endoplasmic reticulum (ER), we examined the proximity of EGFR and ER by in situ PLA. In this assay, co-localization of two proteins was visualized as fluorescent signals. In HSC-3 cells cultured with no shNFAT5 treatment, we observed decreases of fluorescent signals upon hyperosmotic stimuli (Fig. 2d(c, d), e(b)). These results indicate that NFAT5 is essential for the glycosylation of EGFR in ER.

NFAT5 increases the expression of DPAGT1 by binding to the promoter region under hyperosmotic conditions

We hypothesized that glycosylation of EGFR in ER is important for cell proliferation. We examined some
Fig. 2 Translocation of NFAT5 into the nucleus activates EGFR phosphorylation and dissociation of pEGFR from the ER in HSC-3 cells under hyperosmotic conditions. a Immunofluorescent cytochemical staining of NFAT5 (green) for HSC-3 cells. Immunoreaction is predominantly seen in nucleus in LG + mannitol (c) compared to the cytosolic reaction in LG (a). Scale bars = 20 µm. b Preliminary inhibition analysis of NFAT5 mRNA expression with two different shRNAs specific for NFAT5 (shNFAT5s) on HSC-3 cells in LG by Real-time qPCR method. c Western blot analysis of phosphorylated EGFR (pEGFR), EGFR and NFAT5 expression in control sh(-) and NFAT5-silenced (shNFAT5) HSC-3 cells. In control sh(-) cells in LG and LG + mannitol, the band equivalent for NFAT5 is distinct but indistinct in shNFAT5 cells in LG and LG + mannitol. In control sh(-) cells, the band of non-glycosylated 140 kDa EGFR is apparent in LG but indistinct in LG + mannitol. pEGFR expression is also detected in LG and is upregulated in LG + mannitol in control sh(-) cells. In contrast, shNFAT5 cells, the expression of 140 kDa EGFR is apparent and no obvious change is seen in 170 kDa/140 kDa EGFR expression ratio in LG and LG + mannitol. In addition, expression of pEGFR is not distinct in LG and LG + mannitol in shNFAT5 cells. β-actin = Endogenous control. d In situ proximity ligation assay to confirm the effect of hyperosmolarity. Co-localization of EGFR and KDEL which are secondary labeled by PLA probes (red dots; arrow) is apparent in both control sh (-) (a) and shNFAT5 (c) cells in LG, and also in shNFAT5 cells in LG + mannitol (d). However, the co-localization is indistinct in control sh (-) cells in LG + mannitol (b). Scale bars = 20 µm. e The bar graphs indicate quantitative values of PLA signals. The signal is statistically lower in LG + mannitol (50 mM) in control sh(-) cells (a) and in shNFAT5 cells (b). Together with the results in d, it is considered that NFAT5 dissociates co-localization of EGFR and KDEL in control sh (-) cells in LG + mannitol. Statistical significance assessed by Student’s t test is indicated by *p < 0.05 and **p < 0.01.
regulators involved in N-glycosylation and focused on DPAGT1, which is the first enzyme in the pathway for protein N-glycosylation. We analyzed DPAGT1 expression and found that hyperosmotic stimuli induced and increased the expression of DPAGT1 in accordance with the increase of hyperosmotic stimuli (Fig. 3a, b). The same trend was observed in HSC-4 cells (Supplementary Fig. 2B). Conversely, the expression of 140 kDa EGFR was decreased with the increase of hyperosmotic stimuli (Fig. 3b). Moreover, RT-qPCR analyses revealed that NFAT5 silencing by two different shNFAT5s reduced mRNA levels of DPAGT1 (Fig. 3c).

We performed ChIP analyses to assess whether NFAT5 was bound to the DPAGT1 promoter region, and found that NFAT5 bound to the DPAGT1 promoter region in HSC-3 cells cultured under hyperosmotic conditions (Fig. 3d). These results suggest that hyperosmotic stimuli upregulate the expression of DPAGT1 by the activation of NFAT5.

Tumorigenicity of HSC-3 cells can be accelerated, depending on hyperosmotic stress in vivo

We investigated the effect of hyperosmotic stress on the tumorigenicity of HSC-3 cell xenografts using BALB/cAICl- nu mice (Fig. 4a). HSC-3 cells were injected into the right flank of the mice. After 1 week from the injection, a microosmotic pump was implanted in the right flank to sustain the release of PBS or mannitol into the microenvironment of the transplanted HSC-3 cells. HSC-3 tumorigenicity was significantly accelerated depending on hyperosmotic stress induced by the sustained release of mannitol (Fig. 4b). Histopathologically, tumors showed prominent invasive growth at the tumor front in the hyperosmotic stress group (Fig. 4c(e)). On the other hand, tumors of the PBS control group revealed an expansive growth with a clear margin at the tumor front (Fig. 4c(a)). Immunohistochemically, NFAT5 and DPAGT1 expression were both upregulated in the tumor cells of the hyperosmotic stress

---

**Fig. 3** Expression and subcellular localization of DPAGT1 in HSC-3 cells under hyperosmotic condition. **a** Immunofluorescent cytochemical staining of DPAGT1 (green) in HSC-3 cells. Cytoplasmic expression is seen in LG(a), but perinuclear expression is distinct in LG + mannitol(c). Blue: Nuclear counter staining by DAPI. Scale bars = 20 µm. **b** Western blot analysis of EGFR, NFAT5 and DPAGT1 in HSC-3 cells. DPAGT1 expression is seen in LG and becomes stronger in accordance with the increase of hyperosmolarity. Conversely, 140 kDa EGFR expression becomes obscure in accordance with the increase of hyperosmolarity and DPAGT1 expression. No obvious change is seen in NFAT5 expression in LG and LG + Mannitol. β-actin = Endogenous control. **c** Real-Time qPCR analysis of DPAGT1 mRNA expression in HSC-3 cells. #1 shNFAT5 repress DPAGT1 mRNA expression with a statistical significance. Same tendency but with no statistical significance is seen in the inhibition assay using #2 shNFAT5. **d** Chromatin immunoprecipitation (ChIP) assay to clarify NFAT5 binding to DPAGT1 promoter region in HSC-3 cells. Co-immunoprecipitation of NFAT5 with DPAGT1 promoter region is seen as a band with anti-NFAT5 antibody immunoreaction in LG + mannitol(50 mM) (NFAT5#). Anti-Histon H3 and IgG antibodies are used for positive and negative control, respectively. Statistical significance assessed by Student’s t test is indicated by *p < 0.05.
group (Fig. 4c(f, g)) compared to those in the tumor cells of the PBS control group (Fig. 4c(b, c)). The membranous expression of EGFR was also upregulated in the tumor cells of the hyperosmotic stress group (Fig. 4c(h)) compared to those in the tumor cells of the control group (Fig. 4c(d)).

**Immunohistochemical analysis of NFAT5, DPAGT1, and EGFR expression in OSCC in vivo**

We immunohistochemically analyzed the distribution of NFAT5, EGFR, and DPAGT1 protein expression in human tongue OSCC specimens. Well to moderately differentiated OSCC cells were clearly stained with an anti-NFAT5 antibody in their nuclei (Fig. 5; arrows in a, c and f, and merge e and h). EGFR and DPAGT1 were expressed on the cancer cell surface (Fig. 5; arrowheads in d and merge e) and in the perinuclear area (Fig. 5; arrowheads in g and merge h), respectively. Next, these expression were analyzed in the precancerous lesion of OED and well (W), moderately (M), and moderately to poorly and poorly (MP&P) differentiated OSCCs. The NFAT5 intra-nuclear expression was weak or not apparent in OED (Fig. 6a(a)), but apparent in each differentiation degree of OSCC (Fig. 6a(b–d)). The strong intranuclear expression of NFAT5 was seen especially in the invasive and poorly differentiated cancer cells in M and MP&P OSCCs (Fig. 6a(c, d)). Similarly, DPAGT1 expression was weak or not apparent in OED (Fig. 6a(e)), but apparent in each differentiation degree of OSCC (Fig. 6a(f–h)). Furthermore, the membranous expression of EGFR was apparent in accordance with the strength of the NFAT5 intra-nuclear and
DPAGT1 cytoplasmic/perinuclear expression (Fig. 6a(i–l)). Finally, expression total scores (TSs) were compared among OED and each differentiation degree of OSCC by as described in materials and methods. TSs of NFAT5 and DPAGT1 expression in each differentiation of OSCC were significantly higher than those in OED, and TS in OSCC was gradually increased in accordance with the poor differentiation. A statistical difference was seen between W and MP&P in each NFAT5 and DPAGT1 expression (Fig. 6b(a, b)).

Discussion

In the cancer microenvironment, cancer cells are exposed to starvation, hypoxia and solid stress, and these factors impact on cancer progression [18–21]. In general, the cancer microenvironment is constantly in flamed and inflammatory responses against cancer cells play an important role in cancer development [7, 8]. Previous researchers have studied the relationship between inflammatory cytokines and cancer cell progression in the cancer microenvironment, but osmolarity is also elevated in the cancer microenvironment. Cancer cells are constantly undergoing apoptosis and necrosis especially in the center of the cancer cell nests, because hypoxia and starvation occur due to the low resorption of oxygen. Intracellular potassium ions are then released from the apoptotic or necrotic cancer cells into the extracellular fluid, resulting in the elevation of osmolarity [22]. However, the role of hyperosmotic stress on cancer cell proliferation is not fully understood. In this study, we found that NFAT5 was upregulated in OSCC cancer cells in association with the upregulation of DPAGT1. In addition, in vitro studies using HSC-3 cells revealed that hyperosmotic stress upregulated cell proliferation and NFAT5 expression which resulted in changes in the subcellular localization of EGFR from the cytoplasm to the plasma membrane.

Cancer cells display a high rate of glycolysis rather than oxidative phosphorylation for energy production. Therefore, glucose utilization of cancer cells is greatly enhanced [23, 24]. Consequently, it is thought that glucose levels in the microenvironment surrounding tumor cells are decreased [19, 25]. A previous report revealed that glucose concentrations were much lower in tumor than normal tissue in colon and stomach cancer [25]. To mimic this condition, we first cultured cancer cells in LG medium, and immunocytochemically observed EGFR expression predominantly in the cytoplasm, especially in the perinuclear region. In addition, we detected unglycosylated EGFR of 140 kDa which is not observed in the plasma membrane fraction by Western blotting analyses. Next, we investigated EGFR expression in HSC-3 cells under hyperosmotic conditions. To mimic hyperosmotic conditions, cells were cultured in LG medium with mannitol, which is an impermeable material. When cells were cultured under hyperosmotic conditions, we observed the EGFR expression predominantly in the plasma membrane and detected a glycosylated form of 170 kDa; whereas the unglycosylated EGFR (140 kDa) was faint by Western blot analyses. These
results indicate that glycosylation of EGFR was essential for its subcellular translocation from the cytoplasm to the plasma membrane under hyperosmotic conditions. In addition, the addition of NaCl has been also known to elevate the osmolarity of medium, and we also observed the same finding of the subcellular EGFR translocation from the...
cytoplasm to the plasma membrane when cells were cultured in medium with NaCl (data not shown). Furthermore, upregulation of cancer cell proliferation was observed in accordance with the increase of the osmolarity of medium, and was then suppressed by CP380736, a specific EGFR inhibitor, and genistein, a non-specific TKI. Thus, these results indicate that not only glucose concentration but also osmolarity in the cancer microenvironment were critical factors for the enhancement of the EGFR signaling pathway in cancer cell progression.

NFAT5 is a transcription factor activated under hyperosmotic conditions and was initially reported to play a role in orchestrating a genetic program to restore cellular homeostasis in the hypertonic kidney inner medulla. When cells are exposed to osmotic stress, NFAT5 activates transcription of several osmoadaptive genes to restore biochemical homeostasis [26]. Some previous studies showed activation of NFAT5 in colon, renal, and breast cancer [27–29]. To investigate the role of NFAT5 in OSCC, we knocked down the gene using short hairpin RNA. Interestingly, the translocation of EGFR from ER toward plasma membrane and glycosylation of EGFR in hyperosmotic stress were significantly inhibited by shRNA for NFAT5 in HSC-3 OSCC cells. In addition, RT-qPCR analysis revealed that DPAGT1 gene expression was suppressed by knockdown of NFAT5. From these findings, it appears that EGFR subcellular translocation and glycosylation was triggered at least by the activation of NFAT5.

To clarify that NFAT5 directly regulated the DPAGT1 upregulation in HSC-3 cells by binding the promoter region of DPAGT1, we performed a ChIP assay. The assay revealed that NFAT5 protein bond to the DPAGT1 promoter region in HSC-3 cells under hyperosmotic conditions. The DPAGT1 gene encodes dolichol phosphate-dependent N-acetylglucosamine-1-phosphate transferase, which catalyzes the initial reaction required for synthesis of dolichol-P-P-oligosaccharides in the ER [30]. Previous studies reported that DPAGT1 gene and proteins were highly expressed in OSCC, and regulated cancer cell proliferation [31–33]. Nita-Lazar et al. reported that over expression of DPAGT1 induced aberrant glycosylation of E-cadherin and discohesion in oral cancer cells, leading to the induction of cancer cell migration [31]. It is reasonable to propose that DPAGT1 plays a pivotal role in both cell proliferation and migration. In a murine melanoma in vivo model, Kim et al. demonstrated that NFAT5 was critical for melanoma cell proliferation and metastasis [34]. In our analyses, NFAT5 and DPAGT1 protein expression was upregulated in the cells of the xenografts under a hyperosmotic cancer microenvironment, and contributed to the enhancement of the progression and invasion of cancer cells of the tumor mass formed by transplanted HSC-3 cells. These findings indicate that NFAT5 may play a pivotal role in the enhancement of the progression of OSCC. We also observed distinct perinuclear and nuclear immunoreactions of DPAGT1 and NFAT5 proteins in human OSCC cells, respectively. In addition, both expression TS scores were increased in accordance with the increased histological degrees of OSCC. Overall, these results demonstrate that hyperosmotic stress contributed to the activation of DPAGT1 and the subcellular translocation of EGFR via NFAT5 induction in the tumor microenvironment (Fig. 6c).

In summary, we determined that NFAT5 enhanced the progression of OSCC cells under hyperosmotic conditions by activating DPAGT1 and the glycosylation of EGFR, which resulted in the a change of EGFR subcellular localization from the cytoplasm to the plasma membrane. Our present study may provide a new insight into a potential therapeutic target for OSCC.

Acknowledgements This work was supported in part by Grants-in-Aid for Scientific Research (C) (18K07033 to SH), Grant-in-Aid for Young Scientists (B) (17K18301 to SY) and Grants-in-Aid for Young Scientists (20K18490 to SY) from Japan Society for the Promotion of Science (JSPS)/KAKENHI.

Author contributions SY and HM: Contributed to conception, design, data acquisition and interpretation, performed all statistical analyses, drafted and critically revised the paper. MM and YK: Contributed to data acquisition and interpretation. MH: Contributed to conception, design, and critically revised the paper. SH: Contributed to conception, design, data acquisition and interpretation, drafted and critically revised the paper.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethics This study was performed with the approval of the Ethics Committee of Fukuoka Dental College, and informed consent was obtained from all patients (project identification code: No. 312). This study was performed in accordance with the Declaration of Helsinki. All animal studies were approved by Fukuoka Dental College, Institutional Animal Care and Use Committee (project identification code: No. 17001).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303.

2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.

3. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8.

4. Bardelli A, Jänne PA. The road to resistance: EGFR mutation and cetuximab. Nat Med. 2012;18:199–200.

5. Stransky N, Egloff AM, Tward AD, Kostic AD, CibuIuskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–60.

6. Lawrence MS, Sougnez C, Lichtenstein L, CibuIuskis K, Lander E, Gabriel SB, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–82.

7. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammatory-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.

8. Oshima H, Nakayama M, Han T-S, Naoi K, Ju X, Maeda Y, et al. Suppressing TGFbeta signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. Cancer Res. 2015;75:766–76.

9. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105:1–8.

10. Kubota K, Moriyama M, Furukawa S, RafiuI HASM, Maruse Y, Jinno T, et al. CD163⁺ CD204⁺ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma. Sci Rep. 2017;7:1–12.

11. Lopez-Rodriguez C, Aramburu J, Rakeman S, Rao A. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc Natl Acad Sci USA. 1999;96:7214–9.

12. Miyakawa H, Woo SK, Dahl SC, Handler JS, Kwon HM. Toxicity-responsive enhancer binding protein, a rEl-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci USA. 1999;96:2538–42.

13. Daniel C, Gerlach K, Väth M, Neurath MF, Weigmann B. Nuclear factor of activated T cells—a transcription factor family as critical regulator in lung and colon cancer. Int J Cancer. 2014;134:1767–75.

14. Tran Quang C, Leboucher S, Passaro D, Fuhrmann L, Nourieh M, Vincent-Salomon A, et al. The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells. Cell Death Dis. 2015;6:e1658.

15. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Sloopwijk PJ, WHO classification of head and neck tumours. 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.

16. Tanaka F, Yoshimoto S, Okamura K, Ikebe T, Hashimoto S. Nuclear PKM2 promotes the progression of oral squamous cell carcinoma by inducing EMT and post-translationally repressing TGFβ2. Oncotarget. 2018;9:33745–61.